18.80
Schrodinger Inc stock is traded at $18.80, with a volume of 510.73K.
It is down -2.08% in the last 24 hours and up +0.16% over the past month.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
See More
Previous Close:
$19.20
Open:
$18.81
24h Volume:
510.73K
Relative Volume:
0.45
Market Cap:
$1.41B
Revenue:
$254.91M
Net Income/Loss:
$-103.48M
P/E Ratio:
-13.39
EPS:
-1.4036
Net Cash Flow:
$-148.35M
1W Performance:
-9.22%
1M Performance:
+0.16%
6M Performance:
+48.85%
1Y Performance:
+3.58%
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, TXG, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SDGR
Schrodinger Inc
|
18.80 | 1.41B | 254.91M | -103.48M | -148.35M | -1.4036 |
|
VEEV
Veeva Systems Inc
|
260.98 | 42.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
57.88 | 11.45B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
58.74 | 10.66B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
TXG
10 X Genomics Inc
|
66.38 | 8.65B | 638.78M | -22.66M | 122.18M | -0.1744 |
|
HQY
Healthequity Inc
|
94.55 | 7.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Neutral |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrödinger introduces Tectora Therapeutics - bioworld.com
Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc. - marketscreener.com
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs - BioSpace
SDGR Looks 19.2% Undervalued on GF Value™ - GuruFocus
Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates - marketscreener.com
A new drug company raises $55 million for oral medicines - Stock Titan
Is Schrodinger Inc (SDGR) a Bargain After 3.1% Drop? GF Value Sa - GuruFocus
Schrodinger (SDGR) Slips 1.3% as Shares Hold Above Key $19.58 SupportPut Flow Alert - dars.gov.et
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - TradingView
“Schrodinger’s Strait:” Why Hormuz Now Exists in a State of Permanent Uncertainty - Yahoo Finance
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 - PR Newswire
Schrödinger’s Strait - الحرة
Price-Driven Insight from (SDGR) for Rule-Based Strategy - Stock Traders Daily
Drug Discovery Platforms Market to Reach USD 16.5 Billion by 2036, Driven by AI-Powered Research and Rising Pharmaceutical R&D Investment - industrytoday.co.uk
Schrödinger to Present at Morgan Stanley Global Healthcare Conference 2026 - BioSpace
Schrödinger to Present at Morgan Stanley Global Healthcare Conference - Yahoo Finance
Schrodinger Inc. (SDGR) Slips 1.81% to $20.04 as Stock Holds Above Key SupportInsider Selling Alerts - dars.gov.et
SDGR | Schrodinger, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Schrödinger: The Software Business Is Stronger Than It Looks (NASDAQ:SDGR) - Seeking Alpha
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript - AOL.com
Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR - MarketBeat
Schrodinger (NASDAQ:SDGR) Trading 10.4% HigherWhat's Next? - MarketBeat
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Schrodinger Inc (SDGR) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery - drugdiscoverytrends.com
Schrodinger Inc. (SDGR) Slides 4.7% to $17.59 as Bearish Momentum BuildsCounter Trend Trade - Vinanet
SDGR Looks 29.7% Undervalued on GF Value™ - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Schrodinger (SDGR) Slides 4.7% to $17.59 as Selling Pressure MountsSynthetic Short - Vinanet
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Sc - GuruFocus
UBS initiates Schrodinger stock coverage with neutral rating By Investing.com - Investing.com South Africa
SDGR Assumed by UBS -- Price Target Raised to $19.00 - GuruFocus
UBS Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Schrodinger Coverage Assumed by UBS at Neutral - Moomoo
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Two New Schrödinger Hires Get Stock Awards Vesting Over Four Years - Stock Titan
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
UBS initiates Schrodinger stock coverage with neutral rating - Investing.com Nigeria
UBS Initiates Schrodinger(SDGR.US) With Hold Rating, Announces Target Price $19 - Moomoo
Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Schrodinger, Inc. (SDGR) Stock Forecasts - Yahoo! Finance Canada
Technical Reactions to SDGR Trends in Macro Strategies - Stock Traders Daily
Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR - MarketBeat
Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 ProfitabilityHas The Bull Case Changed? - simplywall.st
Schrödinger Unveils Bunsen, an AI Co-Scientist for Enhanced Molecular Discovery - SynBioBeta
SDGR Q2 2026 Earnings: EPS of $0.08 Beats Estimates with a 116.27% SurpriseReturn On Capital - vinanet.vn
Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR - MarketBeat
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - webull.com
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):